Healthcare-associated Infectious Disease Diagnostics Market by Product & Service (Assays, Kits & Reagents, Instruments, Services & Software), Disease Type (Chlamydia Trachomatis Genital Infection & Gonorrhea, Hepatitis, Hospital-Acquired Infections), End-

Healthcare-associated Infectious Disease Diagnostics Market by Product & Service (Assays, Kits & Reagents, Instruments, Services & Software), Disease Type (Chlamydia Trachomatis Genital Infection & Gonorrhea, Hepatitis, Hospital-Acquired Infections), End-user - Global Forecast 2024-2030


The Healthcare-associated Infectious Disease Diagnostics Market size was estimated at USD 4.04 billion in 2023 and expected to reach USD 4.37 billion in 2024, at a CAGR 8.35% to reach USD 7.09 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Healthcare-associated Infectious Disease Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Healthcare-associated Infectious Disease Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Healthcare-associated Infectious Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomérieux SA, Co-Diagnostics Inc., Danaher Corporation, DiaSorin S.p.A., DNAe Group Holdings Ltd, GNA Biosolutions GmbH, Meridian Bioscience Inc. by SD Biosensor, Qiagen N.V., Quidel Corporation, Roche Holding AG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage



This research report categorizes the Healthcare-associated Infectious Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product & Service
Assays, Kits & Reagents
Instruments
Services & Software
Disease Type
Chlamydia Trachomatis Genital Infection & Gonorrhea
Hepatitis
Hospital-Acquired Infections
Human Immunodeficiency Virus
Human Papillomavirus
Influenza
Tuberculosis
End-user
Academic & Research Institutes
Hospital & Clinical Laboratories
Physician Offices
Reference Laboratories
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Healthcare-associated Infectious Disease Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Healthcare-associated Infectious Disease Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Healthcare-associated Infectious Disease Diagnostics Market?
4. What is the market share of the leading vendors in the Healthcare-associated Infectious Disease Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Healthcare-associated Infectious Disease Diagnostics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Healthcare-associated Infectious Disease Diagnostics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Shift in focus from centralized laboratories to decentralized point-of-care testing
5.1.1.2. Growth in funding for research on infectious disease diagnostics
5.1.2. Restraints
5.1.2.1. Stringent regulations to prevent HAIs in healthcare settings
5.1.2.2. Sophisticated mechanisms available to control HAIs
5.1.3. Opportunities
5.1.3.1. Increase in target patients with healthcare-associated infections
5.1.3.2. High growth potential in low and middle-income countries
5.1.3.3. Growing penetration of POC tests to diagnose HAIs
5.1.4. Challenges
5.1.4.1. Inadequate reimbursements
5.1.4.2. Low prevalence of HAIs in high-income nations
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Healthcare-associated Infectious Disease Diagnostics Market, by Product & Service
6.1. Introduction
6.2. Assays, Kits & Reagents
6.3. Instruments
6.4. Services & Software
7. Healthcare-associated Infectious Disease Diagnostics Market, by Disease Type
7.1. Introduction
7.2. Chlamydia Trachomatis Genital Infection & Gonorrhea
7.3. Hepatitis
7.4. Hospital-Acquired Infections
7.5. Human Immunodeficiency Virus
7.6. Human Papillomavirus
7.7. Influenza
7.8. Tuberculosis
8. Healthcare-associated Infectious Disease Diagnostics Market, by End-user
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Hospital & Clinical Laboratories
8.4. Physician Offices
8.5. Reference Laboratories
9. Americas Healthcare-associated Infectious Disease Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Becton, Dickinson and Company
13.1.3. Bio-Rad Laboratories, Inc.
13.1.4. Biomérieux SA
13.1.5. Co-Diagnostics Inc.
13.1.6. Danaher Corporation
13.1.7. DiaSorin S.p.A.
13.1.8. DNAe Group Holdings Ltd
13.1.9. GNA Biosolutions GmbH
13.1.10. Meridian Bioscience Inc. by SD Biosensor
13.1.11. Qiagen N.V.
13.1.12. Quidel Corporation
13.1.13. Roche Holding AG
13.1.14. Siemens Healthineers AG
13.1.15. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET DYNAMICS
FIGURE 7. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
FIGURE 8. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 10. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings